RxDoctor Payments Data

Kent Covert, MD

Family Medicine · Springdale, ARNPI 1568414415

Payments from drug & device makers

$11,019in general payments, 2019–2025

Across 766 payments — averaging $14.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$840
  • Astellas Pharma US Inc$736
  • GSK$689
  • plus $5K from 43 others

What the payments were for

  • Food & beverage$10,80498%
  • Education$2152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,019 in reported general payments places this provider in the 95th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$74,321
Medicare patients
215
Services billed
2,387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin31$41,230
EliquisApixaban17$29,229
OzempicSemaglutide20$22,696
MounjaroTirzepatide16$15,431
FarxigaDapagliflozin Propanediol12$8,204
Celecoxib76$2,293
Gabapentin74$1,810
Atorvastatin Calcium173$1,686
Losartan Potassium221$1,681
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,526
PaxlovidNirmatrelvir/Ritonavir13$1,429
Rosuvastatin Calcium123$1,394
Pregabalin13$1,336
Levothyroxine Sodium107$1,074
Estradiol (Once Weekly)Estradiol18$1,063

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$140$41,23031 claims
PfizerEliquis, Paxlovid$379$30,65830 claims
Novo NordiskOzempic$578$22,69620 claims
Lilly USA, LLCMounjaro$840$15,43116 claims
AstraZenecaFarxiga$1,075$8,20412 claims
AbbVieSynthroid$1,413$81915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Springdale

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →